Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis

Tumor programmed cell death ligand-1 (PD-L1) expression is a key biomarker to identify patients with non-small cell lung cancer who may have an enhanced response to anti-programmed cell death-1 (PD-1)/PD-L1 treatment. Such treatments are used in conjunction with PD-L1 diagnostic immunohistochemistry...

Descripción completa

Detalles Bibliográficos
Autores principales: Widmaier, Moritz, Wiestler, Tobias, Walker, Jill, Barker, Craig, Scott, Marietta L., Sekhavati, Farzad, Budco, Alexei, Schneider, Katrin, Segerer, Felix J., Steele, Keith, Rebelatto, Marlon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051919/
https://www.ncbi.nlm.nih.gov/pubmed/31527709
http://dx.doi.org/10.1038/s41379-019-0349-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051919/
https://www.ncbi.nlm.nih.gov/pubmed/31527709
http://dx.doi.org/10.1038/s41379-019-0349-y

Ejemplares similares